About: Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $50.76 (-1.36%)
CYTK NASDAQ Cytokinetics Inc
Cytokinetics Inc share price
Atividade de preço de CYTK
Último preço
$ 50,760
Variação (24h)
-0,70 USD (1,36%)
Volume
1.17M
Volume (média 4 sem.)
-
Abertura
$ 51,23
Variação do dia
$ 50,60 - $ 53,38
Fechamento anterior
$ 51,46
Último negócio
20 Nov, 9:00 pm GMT+0
Atrasado
20 Nov, 9:00 pm GMT+0
CYTK price performance
Atrasado
20 Nov, 9:00 pm GMT+0
CYTK details
quote.marketSignals